

DRAFT
DO NOT CITE OR QUOTE

EPA/600/P-00/001Be
September 2000
Draft Final
www.epa.gov/ncea

Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodibenzo-*p*-Dioxin (TCDD) and Related Compounds

Part II: Health Assessment for 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) and Related Compounds

Chapters 1 through 7

National Center for Environmental Assessment
Office of Research and Development
U.S. Environmental Protection Agency
Washington, DC

DISCLAIMER

This document is a draft. It has not been formally released by the U.S. Environmental Protection Agency and should not at this stage be construed to represent Agency policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

TABLE OF CONTENTS - OVERVIEW

Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds

Part I: Estimating Exposure to Dioxin-Like Compounds (Draft Final) (EPA/600/P-00/001 Bb, Bc, Bd) September 2000

Volume 1: Executive Summary (EPA/600/P-00/001Ba) (**Vol. 1 is not included in this draft.**)

Volume 2: Sources of Dioxin-Like Compounds in the United States (EPA/600/P-00/001Bb)
Chapters 1 through 13

Volume 3: Properties, Environmental Levels, and Background Exposures
(EPA/600/P-00/001Bc)
Chapters 1 through 6

Volume 4: Site-Specific Assessment Procedures (EPA/600/P-00/001Bd)
Chapters 1 through 8

Part II: Health Assessment for 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and Related Compounds (Draft Final) (EPA/600/P-00/001Be) September 2000

- Chapter 1. Disposition and Pharmacokinetics
- Chapter 2. Mechanism(s) of Actions
- Chapter 3. Acute, Subchronic, and Chronic Toxicity
- Chapter 4. Immunotoxicity
- Chapter 5. Developmental and Reproductive Toxicity
- Chapter 6. Carcinogenicity of TCDD in Animals
- Chapter 7. Epidemiology/Human Data

- Chapter 8. Dose-Response Modeling for 2,3,7,8-TCDD
(SAB Review Draft, September 2000)
- Chapter 9. Toxic Equivalency Factors (TEF) for Dioxin and Related Compounds
(SAB Review Draft, September 2000)

Part III: Integrated Summary and Risk Characterization for 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds (SAB Review Draft, September 2000) (EPA/600/P-00/001Bg)

CONTENTS

1.	DISPOSITION AND PHARMACOKINETICS	1-1
1.1.	ABSORPTION/BIOAVAILABILITY FOLLOWING EXPOSURE	1-1
1.1.1.	Oral	1-1
1.1.1.1.	Gastrointestinal Absorption in Animals	1-1
1.1.1.2.	Gastrointestinal Absorption in Humans	1-3
1.1.1.3.	Bioavailability Following Oral Exposure	1-5
1.1.2.	Dermal Absorption	1-6
1.1.2.1.	Bioavailability Following Dermal Exposure	1-8
1.1.3.	Transpulmonary Absorption	1-9
1.1.4.	Parenteral Absorption	1-11
1.2.	DISTRIBUTION	1-11
1.2.1.	Distribution in Blood and Lymph	1-11
1.2.2.	Tissue Distribution	1-13
1.2.2.1.	Tissue Distribution in Humans	1-16
1.2.3.	Time-Dependent Tissue Distribution	1-18
1.2.4.	Dose-Dependent Tissue Distribution	1-23
1.2.5.	Potential Mechanisms for Dose-Dependent Tissue Distribution	1-25
1.3.	METABOLISM AND EXCRETION	1-29
1.3.1.	Structure of Metabolites	1-30
1.3.2.	Toxicity of Metabolites	1-32
1.3.3.	Autoinduction of Metabolism	1-33
1.3.4.	Excretion in Animals	1-37
1.3.5.	Excretion in Humans	1-40
1.4.	PHARMACOKINETICS AND EXPOSURE	1-45
1.4.1.	Introduction	1-45
1.4.2.	Estimating Daily Intake of TCDD	1-46
1.4.3.	Daily Intake of Congeners	1-48
1.4.4.	Induction of Liver Binding Proteins and Resultant Distribution	1-51
1.4.5.	Pregnancy and Lactation (Exposure of Offspring)	1-51
1.4.6.	Pharmacokinetics and Aging	1-60
1.5.	SELECTION OF DOSE SURROGATE	1-61
1.5.1.	Administered Dose	1-62
1.5.2.	Area Under the Curve	1-63
1.5.3.	Plasma or Tissue Concentrations	1-64
1.5.4.	Steady-State Body Burdens	1-65
1.5.5.	Mechanistic Dose Metrics	1-66
1.5.6.	Summary	1-66
	REFERENCES FOR CHAPTER 1	1-95
2.	MECHANISM(S) OF ACTION	2-1
2.1.	INTRODUCTION	2-1
2.2.	THE "RECEPTOR" CONCEPT	2-2
2.3.	THE Ah (DIOXIN) RECEPTOR	2-4

CONTENTS (continued)

2.4. THE ARNT PROTEIN	2-8
2.5. OTHER PROTEINS THAT PARTICIPATE IN THE RESPONSE TO DIOXIN	2-10
2.6. ACTIVATION OF GENE TRANSCRIPTION BY DIOXIN	2-12
2.6.1. In Vitro Studies	2-12
2.6.2. In Vivo Studies	2-15
2.7. EVIDENCE FOR DIFFERENT MECHANISMS OF TOXICITY	2-17
2.8. FUTURE RESEARCH	2-21
2.9. MECHANISTIC INFORMATION AND RISK ASSESSMENT	2-25
REFERENCES FOR CHAPTER 2	2-31
3. ACUTE, SUBCHRONIC, AND CHRONIC TOXICITY	3-1
3.1. SCOPE AND LIMITATIONS	3-1
3.2. ACUTE TOXICITY	3-1
3.2.1. Signs and Symptoms of Toxicity	3-4
3.2.2. Studies In Vitro	3-5
3.2.3. Appraisal	3-6
3.3. SUBCHRONIC TOXICITY	3-6
3.3.1. Appraisal	3-8
3.4. CHRONIC TOXICITY	3-9
3.4.1. Appraisal	3-10
3.5. SPECIFIC EFFECTS	3-10
3.5.1. Wasting Syndrome	3-10
3.5.2. Hepatotoxicity	3-13
3.5.3. Epidermal Effects	3-16
3.5.4. Enzyme Induction	3-17
3.5.4.1. Appraisal	3-20
3.5.5. Endocrine Effects	3-20
3.5.6. Vitamin A Storage	3-23
3.5.7. Lipid Peroxidation	3-25
3.5.8. Neurotoxicity	3-27
3.6. MECHANISMS OF TOXICITY	3-28
3.7. SUMMARY	3-32
REFERENCES FOR CHAPTER 3	3-41
4. IMMUNOTOXICITY	4-1
4.1. INTRODUCTION	4-1
4.2. ROLE OF THE AH LOCUS IN PHAH IMMUNOTOXICITY	4-3
4.3. SENSITIVE TARGETS FOR PHAH IMMUNOTOXICITY	4-9
4.4. INFLUENCE OF TCDD ON HOST RESISTANCE TO DISEASE	4-14
4.5. ROLE OF THE THYMUS IN PHAH IMMUNOTOXICITY	4-17
4.6. IMMUNOTOXICITY FOLLOWING PRENATAL/NEONATAL EXPOSURE TO PHAHS	4-19

CONTENTS (continued)

4.7. IMMUNOTOXICITY OF PHAHS IN NONHUMAN PRIMATES	4-22
4.8. IMMUNOTOXICITY OF PHAHS IN HUMANS: IN VIVO EXPOSURE	4-24
4.9. IMMUNOTOXICITY OF PHAHS IN HUMANS: IN VITRO EXPOSURE	4-33
4.10. SUMMARY	4-34
REFERENCES FOR CHAPTER 4	4-42
5. DEVELOPMENTAL AND REPRODUCTIVE TOXICITY	5-1
5.1. INTRODUCTION	5-1
5.2. DEVELOPMENTAL TOXICITY	5-3
5.2.1. Death/Growth/Clinical Signs	5-3
5.2.1.1. Fish	5-3
5.2.1.2. Birds	5-4
5.2.1.3. Laboratory Mammals	5-7
5.2.1.4. Structure-Activity Relationships in Laboratory Mammals	5-14
5.2.1.5. Humans	5-15
5.2.2. Structural Malformations	5-17
5.2.2.1. Cleft Palate	5-19
5.2.2.2. Hydronephrosis	5-27
5.2.2.3. Tooth Development	5-30
5.2.3. Postnatal Effects	5-30
5.2.3.1. Eye Opening	5-30
5.2.3.2. Male Reproductive System	5-31
5.2.3.3. Female Reproductive System	5-58
5.2.3.4. Neurobehavior	5-63
5.2.3.5. Thermoregulation	5-72
5.2.3.6. Auditory Function and Thyroid Hormones	5-73
5.2.3.7. Night Vision	5-75
5.2.4. Cross-Species Comparison of Effect Levels	5-76
5.3. REPRODUCTIVE TOXICITY	5-78
5.3.1. Female	5-78
5.3.1.1. Reproductive Function/Fertility	5-78
5.3.1.2. Ovarian Function	5-80
5.3.1.3. Reproductive Capability of Ah Receptor Knockout Mice	5-80
5.3.1.4. Endometriosis	5-81
5.3.1.5. Mammary Gland	5-82
5.3.1.6. Alterations in Hormone Levels	5-86
5.3.1.7. Antiestrogenic Action	5-86
5.3.2. Male	5-91
5.3.2.1. Reproductive Function/Fertility	5-91
5.3.2.2. Alterations in Hormone Levels	5-92
5.3.2.3. Target Organ Responsiveness	5-92

CONTENTS (continued)

5.4. SUMMARY	5-95
5.4.1. Human	5-95
5.4.2. Experimental Animal	5-96
5.4.2.1. Developmental Toxicity	5-96
5.4.2.2. Adult Female Reproductive Toxicity	5-98
5.4.2.3. Adult Male Reproductive Toxicity	5-98
5.4.3. Conclusion	5-99
REFERENCES FOR CHAPTER 5	5-110
6. CARCINOGENICITY OF TCDD IN ANIMALS	6-1
6.1. INTRODUCTION	6-1
6.2. ANIMAL BIOASSAYS FOR CANCER	6-2
6.2.1. Kociba Study	6-3
6.2.2. NTP Study	6-5
6.2.3. Syrian Golden Hamster	6-6
6.2.4. B6C3 and B6C Mice	6-6
6.2.5. Fish	6-7
6.2.6. Carcinogenicity of Related Compounds	6-7
6.3. INITIATION/PROMOTION STUDIES	6-8
6.3.1. TCDD Is Not a Direct Genotoxic Agent	6-9
6.3.2. Two-Stage Models of Liver Tumor Promotion by TCDD	6-10
6.3.3. Lung	6-12
6.3.4. Mouse Skin	6-13
6.3.5. Transgenic Models	6-14
6.4. MECHANISMS OF TCDD CARCINOGENICITY	6-15
6.4.1. Indirect DNA Damage	6-15
6.4.2. Endocrine Disruption/Growth Dysregulation/Altered Signal Transduction	6-15
6.4.3. Cell Replication/Apoptosis and Tumor Promotion	6-16
6.4.4. Thyroid Cancer—Proposed Mechanism of Action	6-17
6.4.5. Mechanisms of Reduced Spontaneous Tumor Incidence	6-18
6.5. BIOCHEMICAL RESPONSES	6-19
6.5.1. Cytochrome P450	6-19
6.5.2. Epidermal Growth Factor Receptor	6-24
6.5.3. UDP-Glucuronosyltransferases	6-26
6.5.4. Estrogen Receptor	6-28
6.5.5. Other Biochemical Endpoints	6-30
6.6. SUMMARY AND WEIGHT OF EVIDENCE FROM ANIMAL STUDIES	6-30
REFERENCES FOR CHAPTER 6	6-46
7. PART 7A: EPIDEMIOLOGY/HUMAN DATA	7A-1
7.1. INTRODUCTION	7A-1

CONTENTS (continued)

7.2. SCOPE	7A-1
7.3. PREVIOUS EPA REVIEWS	7A-4
7.4. REVIEW METHODS	7A-4
7.5. FOLLOW-UP STUDIES OF CHEMICAL MANUFACTURING AND PROCESSING WORKERS	7A-7
7.5.1. United States	7A-7
7.5.2. Germany	7A-16
7.5.3. Ten-Country Study by International Agency for Research on Cancer	7A-24
7.5.4. Other Studies	7A-29
7.5.5. Summary	7A-36
7.6. CASE-CONTROL STUDIES IN GENERAL POPULATIONS	7A-37
7.6.1. Sweden	7A-38
7.6.2. United States	7A-43
7.6.3. New Zealand	7A-46
7.6.4. Italy	7A-50
7.6.5. Finland	7A-51
7.6.6. Summary	7A-52
7.7. STUDIES OF PULP AND PAPER MILL WORKERS	7A-54
7.8. OTHER STUDIES	7A-56
7.8.1. Vietnam Veterans	7A-56
7.8.2. Residents of Seveso, Italy	7A-60
7.8.3. Rice Oil Poisonings in Taiwan and Japan Involving Compounds Structurally Related to Dioxin	7A-65
7.9. SUMMARY AND CONCLUSIONS	7A-67
7. PART 7B: EFFECTS OTHER THAN CANCER	7B-1
7.10. INTRODUCTION	7B-1
7.11. CROSS-SECTIONAL STUDIES: USES AND LIMITATIONS	7B-2
7.12. DESCRIPTION OF PRINCIPAL STUDIES	7B-4
7.12.1. Occupational Studies	7B-4
7.12.1.1. U.S. Chemical Workers: West Virginia	7B-4
7.12.1.2. U.S. Chemical Workers: The NIOSH Study	7B-5
7.12.1.3. BASF Accident Cohort	7B-6
7.12.2. Studies of Community Residents	7B-7
7.12.2.1. The Missouri Experience	7B-7
7.12.2.2. Seveso, Italy	7B-8
7.12.2.3. Developmental Studies From The Netherlands	7B-9
7.12.3. Studies of Vietnam Veterans	7B-13
7.12.3.1. The Vietnam Experience Study	7B-13
7.12.3.2. U.S. Air Force Ranch Hand Study	7B-14

CONTENTS (continued)

7.12.3.3.	Studies of the Effect of Ingestion of Rice Oil Contaminated With Polychlorinated Dibenzofurans, Quaterphenyls, and Biphenyls in Japan (YUSHO) and Taiwan (YU- CHENG)	7B-16
7.13.	REVIEW OF EFFECTS ASSOCIATED WITH EXPOSURE	
	TO 2,3,7,8-TCDD	7B-17
7.13.1.	Dermal Effects	7B-17
7.13.1.1.	Chloracne	7B-17
7.13.1.2.	Dermatologic Disorders Other Than Chloracne	7B-19
7.13.1.3.	Comment	7B-21
7.13.2.	Gastrointestinal Effects	7B-22
7.13.2.1.	Hepatic Effects	7B-22
7.13.2.2.	Liver Size	7B-22
7.13.2.3.	Enzyme Levels	7B-23
7.13.2.4.	GGT	7B-23
7.13.2.5.	AST and ALT	7B-24
7.13.2.6.	D-Glucaric Acid	7B-27
7.13.2.7.	Porphyrin Metabolism	7B-28
7.13.2.8.	Lipid Levels	7B-30
7.13.2.9.	Total Cholesterol	7B-31
7.13.2.10.	Triglycerides	7B-32
7.13.3.	Other Gastrointestinal Disorders	7B-34
7.13.4.	Thyroid Function	7B-34
7.13.4.1.	Adult Effects	7B-34
7.13.4.2.	Developmental Effects	7B-36
7.13.5.	Adult Reproductive System	7B-37
7.13.5.1.	Hormones	7B-37
7.13.5.2.	Endometriosis	7B-38
7.13.6.	Diabetes	7B-40
7.13.6.1.	Comment	7B-42
7.13.7.	Immunologic Effects	7B-43
7.13.7.1.	Adult Effects	7B-43
7.13.7.2.	Developmental Effects	7B-47
7.13.8.	Neurologic Effects	7B-48
7.13.8.1.	Adult Neurobehavioral Assessments	7B-49
7.13.8.2.	Adult Neurologic Status	7B-52
7.13.8.3.	Developmental Neurobehavioral Effects	7B-55
7.13.8.4.	Comment on Developmental Studies	7B-58
7.13.9.	Circulatory System	7B-59
7.13.9.1.	Comment	7B-64
7.13.10.	Pulmonary Effects	7B-65
7.13.10.1.	Other Mortality Studies of Production Workers	7B-67
7.13.10.2.	Comment	7B-67
7.13.11.	Renal Effects	7B-67

CONTENTS (continued)

7.13.12.	Developmental/Reproductive Effects	7B-68
	Review of the Literature from 1984 through 1995	7B-69
7.13.12.1.	Occupational Studies	7B-69
7.13.12.2.	Environmental Studies	7B-71
7.13.12.3.	Studies of Exposure to Agent Orange by Military Veterans and Vietnamese Civilians	7B-74
	Review of the Literature Prior to 1984	7B-77
7.13.12.4.	Environmental Studies	7B-78
7.13.12.5.	Studies of Vietnam Experience in Ground Troops and Ranch Hands Published 1984-1995	7B-80
7.13.12.6.	New Issues - Developmental Outcomes (1996-1999)	7B-93
7.13.12.7.	Sex Ratio at Birth	7B-94
7.13.12.8.	Growth, Malformations, and Infant Mortality	7B-96
7.13.12.9.	Comment	7B-98
7.14.	NONCANCER EFFECTS OF INGESTION OF RICE OIL CONTAMINATED WITH POLYCHLORINATED DIBENZOFURANS, QUATERPHENYLS, AND BIPHENYLS IN JAPAN (YUSHO) AND TAIWAN (YU-CHENG)	7B-99
7.14.1.	Acute Effects in Adults and Children Directly Exposed to Contaminated Rice Oil	7B-99
7.14.1.1.	Yusho	7B-99
7.14.1.2.	Yu-Cheng	7B-101
7.14.1.3.	Effects Observed in Offspring of Yu-Cheng Cases	7B-102
7.14.1.4.	Mortality Among Yu-Cheng Population	7B-104
7.14.1.5.	Comment	7B-104
7.15.	SUMMARY	7B-105
7.15.1.	Effects Having a Positive Relationship With Exposure to 2,3,7,8-TCDD	7B-109
7.15.1.1.	Chloracne	7B-109
7.15.1.2.	Gamma Glutamyl Transferase (GGT) Levels	7B-110
7.15.1.3.	Reproductive Hormones	7B-112
7.15.2.	Possible Effects of Exposure to 2,3,7,8-TCDD or Mixtures of Dioxins, Furans, and PCBs	7B-114
7.15.2.1.	Possible Adult Effects	7B-114
7.15.2.2.	Possible Postnatal Developmental Effects	7B-116
7.15.3.	Effects for Which Further Research Is Needed	7B-118
7.15.3.1.	Diseases of the Circulatory System	7B-118
7.15.3.2.	Immunologic Effects	7B-120
7.15.3.3.	Adult Reproductive Outcomes	7B-121
7.15.3.4.	Developmental Effects	7B-122
7.15.4.	Acute Effects	7B-126
7.15.4.1.	Dermatologic Conditions Other Than Chloracne	7B-127
7.15.4.2.	Liver Enzymes Other Than GGT and Hepatomegaly	7B-127

CONTENTS (continued)

7.15.4.3. Pulmonary Disorders	7B-128
7.15.4.4. Neurologic Disorders	7B-128
7.15.4.5. Porphyrias	7B-129
7.15.4.6. Thyroid Function	7B-130

LIST OF TABLES

1-1.	Gastrointestinal absorption of TCDD and related compounds following a single oral exposure by gavage	1-68
1-2.	Percentage of TCDD in the liver of rats 24 hours after oral administration of 0.5 mL of various formulations containing TCDD	1-70
1-3.	Dermal absorption of 2,3,7,8-TCDD and related compounds in the rat	1-71
1-4.	Tissue distribution of [¹⁴ C]-2,3,7,8-TCDD in female Wistar rats	1-72
1-5.	2,3,7,8-Substituted PCDDs and PCDFs in human liver and adipose tissue	1-73
1-6.	Elimination of 2,3,7,8-TCDD and related compounds from major tissue depots	1-74
1-7.	Elimination constants and half-lives of various 2,3,7,8-Substituted CDDs and CDFs in hepatic and adipose tissue of marmoset monkeys	1-78
1-8.	TCDD concentrations in liver and adipose tissue following different doses and calculated concentration ratios (liver/adipose tissue	1-80
1-9.	Metabolism and excretion of 2,3,7,8-TCDD and related compounds	1-81
1-10.	Half-life estimates for 2,3,7,8-TCDD and related compound in humans	1-86
1-11.	Calculated daily intakes for TCDD	1-88
1-12.	Half-life calculations	1-89
1-13.	Half-life estimates taken from Flesch-Janys et al. (1996)	1-90
1-14.	Comparison of administered dose and body burden in rats and humans	1-91
2-1.	Events in the activation of <i>CYP1A1</i> gene transcription by dioxin	2-28
3-1.	Acute lethality of TCDD to various species and substrains	3-36
3-2.	Toxic response following exposure to 2,3,7,8-TCDD: species differences	3-38
3-3.	Studies on chronic exposure (except for studies on cancer) to TCDD in laboratory animals	3-39
3-4.	Lowest effect levels for biological responses of 2,3,7,8-TCDD in experimental animals	3-40
4-1.	Acute single dose ID ₅₀ s for polychlorinated dioxins, furans, and biphenyls based on suppression of the PFC response to SRBCs in Ah-responsive B6 mice	4-38
4-2.	ID ₅₀ s for suppression of alloantigen (P815)-specific CTL response in C57Bl/6 mice	4-39
4-3.	Immunotoxic effects of TCDD in the offspring following prenatal/neonatal exposure to TCDD	4-40
5-1.	Relationship between maternal toxicity and prenatal mortality in laboratory mammals exposed to TCDD during gestation	5-100
5-2.	Developmental toxicity following gestational exposure to 2,3,7,8-TCDD	5-101
5-3.	TCDD responsiveness of palatal shelves from the mouse, rat, and human in organ culture	5-104
5-4.	Relative teratogenic potency of halogenated aromatic hydrocarbon congeners in C57BL/6 mice	5-105

LIST OF TABLES (continued)

5-5.	Cross-species comparison of NOAELs and LOAELs for TCDD developmental toxicity in fish	5-106
5-6.	Cross-species comparison of NOAELs and LOAELs for TCDD developmental toxicity in birds	5-107
5-7.	Cross-species comparison of NOAELs and LOAELs for TCDD developmental toxicity in mammals	5-108
6-1.	Sites for increased cancer in animal bioassays	6-33
6-2.	Different evaluations of Kociba study liver tumor data in female rats	6-34
6-3.	Tumor incidences in Osborne-Mendel rats	6-35
6-4.	Tumor incidences in B6C3F ₁ mice	6-36
6-5.	Summary of positive tumor promotion studies for PCDDs and PCDFs in rats	6-37
6-6.	Summary of positive tumor promotion studies for PCDDs and PCDFs in mice	6-38
6-7.	Putatively preneoplastic GGT-positive altered hepatocellular foci (AHF) after 30 weeks of treatment with TCDD as promoter	6-39
6-8.	Preneoplastic altered hepatocellular foci and bromodeoxyuridine labeling indices after 30 weeks of promotion with TCDD	6-40
6-9.	Some biochemical responses to TCDD	6-41
6-10.	Relative potency factors based on tumor promotion/cancer endpoints for "high TEQ contribution" dioxin-like compounds	6-42
7-1.	Relative risks of selected cancers in study of chemical manufacturing workers exposed to TCDD in United States, by exposure duration and latency	7A-71
7-2.	Relative risks of lung cancer in subcohort of chemical manufacturing workers exposed to TCDD in United States for at least 1 year and with at least 20 years latency, adjusted for alternative hypotheses about its smoking distribution	7A-72
7-3.	Life-table results for exposure-level subcohorts: standardized mortality ratios (SMRs) for total cancer by cumulative exposure categories to TCDD content in process materials with and without 15-year lag time for total cancer; U.S. population as referent	7A-73
7-4.	Relative risks of all cancers combined in study of chemical manufacturing workers exposed to TCDD in Germany, by duration and category of exposure	7A-74
7-5.	Relative risks of all cancers combined in study of chemical manufacturing workers exposed to TCDD (ng/kg) in blood in Germany by industry of exposure	7A-75
7-6.	Relative risks of selected cancers in study of chemical manufacturing workers exposed to TCDD in Germany, by median blood TCDD level and latency	7A-76
7-7.	Relative risks of selected cancers in study of chemical manufacturing workers exposed to TCDD in Germany, by TCDD dose ($\mu\text{g}/\text{kg}$ body weight), 1992	7A-77

LIST OF TABLES (continued)

7-8.	Summary of results for selected cancers from follow-up studies of chemical manufacturing and processing workers exposed to TCDD	7A-78
7-9.	Relative risks of soft tissue sarcomas and malignant lymphomas in relation to phenoxy acid and chlorophenol exposures in five case-control studies in Sweden	7A-79
7-10.	Relative risks of malignant lymphoma and soft tissue sarcomas in relation to phenoxy acid and chlorophenol exposures in three case-control studies in Sweden	7A-80
7-11.	Mantel-Haenszel odds ratios for soft tissue sarcoma among persons exposed to all dioxins, TCDD, and dioxins other than TCDD in four case-control studies involving 434 cases and 948 controls	7A-81
7-12.	Relative risks of soft tissue sarcomas, non-Hodgkin's lymphomas, and Hodgkin's disease in relation to phenoxy acid and chlorophenol exposures in two case-control studies in southern Sweden	7A-82
7-13.	Relative risks of non-Hodgkin's lymphomas in relation to farm use of 2,4,5-T in case-control studies in Kansas, eastern Nebraska, Iowa, and Minnesota	7A-83
7-14.	Relative risks of soft tissue sarcomas and non-Hodgkin's lymphomas in relation to phenoxyacetic acid and chlorophenol exposure in a case-control study in western Washington State, 1981-1984	7A-84
7-15.	Relative risks of soft tissue sarcomas and non-Hodgkin's lymphomas in relation to potential exposure to phenoxy acids and chlorophenols in case-control studies in New Zealand	7A-85
7-16.	Relative risks of soft tissue sarcomas in relation to phenoxy acid exposure in case-control study in northern Italy, 1981-1983	7A-86
7-17.	Relative risks for selected cancers from follow-up studies of paper and pulp mill workers	7A-87
7-18.	Relative risks for selected cancers among adults exposed to TCDD in Seveso, Italy	7A-88
7-19.	Relative risks for selected cancers among adults exposed to TCDD in Seveso, Italy, in contaminated areas B and R	7A-89
7-20.	Standard mortality ratios (SMRs) for selected cancers among adults exposed to TCDD in Seveso, Italy, in contaminated areas B and R	7A-90
7-21a.	Standard mortality ratios (SMRs) and relative risks (RRs) of cancer in cohorts with substantial evidence (<i>in vivo</i>) of exposure to dioxin	7A-91
7-21b.	Overview of biologic measurements in Dutch studies of postnatal developmental effects	7B-131
7-22.	Serum 2,3,7,8-tetrachlorodibenzo- <i>p</i> -dioxin (TCDD) levels in Seveso residents with chloracne and adipose tissue levels of 2,3,7,8-TCDD and hexachlorinated (HxCDD) dioxins in German chemical workers	7B-133
7-23.	Mean serum levels of gamma glutamyl transferase (GGT) among Seveso and Missouri residents, TCP production workers, BASF accident cohort, and Vietnam veterans	7B-134

LIST OF TABLES (continued)

7-24.	Logistic regression model for an out-of-range serum gamma-glutamyl transferase (GGT) level using the categorical TCDD ^b exposure measure ^c	7B-136
7-25.	Serum alanine aminotransferase (ALT) among Seveso children and Missouri residents, TCP production workers, BASF accident cohort, and Vietnam veterans	7B-137
7-26.	Blood measures and cumulative dioxin TEQs from 11 weeks of breast feeding (Pluim et al., 1994)	7B-138
7-27.	Mean D-glucaric acid levels among Seveso residents, TCP production workers, and Vietnam veterans	7B-139
7-28.	Mean total cholesterol levels among Seveso and Missouri residents, TCP production workers, BASF accident cohort, and Vietnam veterans	7B-140
7-29.	Mean triglyceride levels among Seveso and Missouri residents, TCP production workers, BASF accident cohort, and Vietnam veterans	7B-142
7-30.	Levels of thyroxine-binding globulin (TBG), thyroxine (T4), free thyroxine (FT4), or T4/TBG	7B-144
7-31.	Levels of triiodothyronine percent (T3%) uptake or free thyroxine index in Vietnam veterans	7B-146
7-32.	Levels of thyroid-stimulating hormone (TSH) in Vietnam veterans	7B-147
7-33.	Levels of thyroid-stimulating hormone (TSH) in nursing infants and BASF accident cohort	7B-148
7-34.	CD4/CD8 ratios in Missouri residents, Vietnam veterans, and BASF accident cohort	7B-149
7-35.	Total lymphocytes in 2,4,5-T production workers, Missouri residents, Vietnam veterans, and BASF accident cohort	7B-150
7-36.	B1 levels in production workers, 2,4,5-T Missouri residents, Vietnam veterans, BASF accident cohort, and extruder personnel	7B-151
7-37.	CD4 levels in production workers, Missouri residents, Vietnam veterans, and BASF chemical workers	7B-152
7-38.	CD8 levels in 2,4,5-T production workers, Missouri residents, Vietnam veterans, and BASF accident cohort	7B-154
7-39.	IgG levels in Missouri residents, Vietnam veterans, and BASF accident cohort	7B-155
7-40.	IgM levels in Missouri residents, Vietnam veterans, BASF accident cohort, and extruder personnel	7B-156
7-41.	Levels of natural killer cells in Missouri residents, Vietnam veterans, and extruder personnel	7B-157
7-42.	Developmental immunologic outcomes (Weisglas-Kuperus et al., 1995)	7B-158
7-43.	Case reports of psychological and neurologic effects among individuals exposed to 2,3,7,8-TCDD-contaminated materials	7B-159
7-44.	Cross-sectional studies of psychological and neurologic effects among residents of Missouri and Seveso exposed to 2,3,7,8-TCDD-contaminated materials	7B-164

LIST OF TABLES (continued)

7-45.	Cross-sectional studies of psychological and neurologic effects among TCP production workers and Vietnam veterans exposed to 2,3,7,8-TCDD-contaminated materials	7B-166
7-46.	Studies of neurologic and behavioral effects among Dutch infants	7B-170
7-47.	Mortality from disease of the circulatory systems in populations exposed to 2,3,7,8-TCDD	7B-174
7-48.	Results of studies examining the effect of dioxin on reproductive and developmental outcomes in humans, 1984-1992	7B-178
7-49.	2,3,7,8-TCDD levels (pg/g of lipid) for selected populations	7B-183
7-50.	Odds ratios for selected categories of birth defects for the telephone interview and hospital records study in the Vietnam experience study, 1989	7B-185
7-51.	Results of the misclassification analyses for birth defects in the hospital records substudy, Vietnam experience study, 1989	7B-186
7-52.	Rates of miscarriage (per 1,000) by pre- and post-Vietnam tour status and time since tour of duty, among 1,475 Ranch Hands with >10 pg/g serum dioxin, Ranch Hand study, 1992	7B-187
7-53.	Summary of effects observed in adults exposed to 2,3,7,8-TCDD	7B-188
7-54.	Effects of exposure to 2,3,7,8-TCDD on serum glucose levels in nonhuman mammalian species	7B-189

LIST OF FIGURES

1-1.	Time course of the connection of 14C-TCDD in rat liver and adipose tissue after a single subcutaneous injection of 300 ng TCDD/kg bw to female rats (M \pm SD)	1-92
1-2.	Dose dependency of the percentage of the administered dose of 14C-TCDD/g of tissue recovered in liver and adipose tissue after single subcutaneous doses (values from animals treated with 3000 ng TCDD/kg bw were corrected for 84% adsorption). Concentrations were measured 7 days after the injection.	1-93
1-3.	Sample calculation of daily intake for TCDD	1-94
2-1.	Chemical structure of dioxin and similar compounds	2-29
2-2.	Cellular mechanisms for Ah receptor action	2-30
4-1.	Structure-dependent immunotoxicity of some polychlorinated dioxin and furan isomers	4-41
6-1.	Schematic representation of multistep carcinogenesis including the roles of genetic damage and cell proliferation	6-44
6-2.	Operational model of TCDD/estrogen interactions relative to tumor promotion in a two-stage model of hepatocarcinogenesis	6-45
6-3.	Plausible mechanism for the role of EGF-mediated stimulation of mitotic activity	6-46